Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.89+0.05 (+6.39%)
Close on Nov 19, 2026Market cap $69.44MP/E –Yield –
Cardiff Oncology gross margin
Gross margin is gross profit as a percentage of revenue.
Cardiff Oncology's gross margin for the twelve months ending Dec 31, 2019 was 100.0%. For fiscal 2019 it was 100.0%, against -57.9% the year before. The highest annual figure on record is 100.0% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 100.0% | +157.9 |
| FY2018 | Dec 31, 2018 | -57.9% | +200.5 |
| FY2017 | Dec 31, 2017 | -258.4% | +95.7 |
| FY2016 | Dec 31, 2016 | -354.1% | −253.0 |
| FY2015 | Dec 31, 2015 | -101.1% | −195.6 |
| FY2014 | Dec 31, 2014 | 94.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | 100.0% | +0.0 |
| Q3 FY2019 | Sep 30, 2019 | 100.0% | +30.2 |
| Q2 FY2019 | Jun 30, 2019 | 100.0% | +182.8 |
| Q1 FY2019 | Mar 31, 2019 | 100.0% | +365.8 |
| Q4 FY2018 | Dec 31, 2018 | 100.0% | +207.3 |
| Q3 FY2018 | Sep 30, 2018 | 69.8% | +353.5 |
| Q2 FY2018 | Jun 30, 2018 | -82.8% | +148.7 |
| Q1 FY2018 | Mar 31, 2018 | -265.8% | +282.8 |
| Q4 FY2017 | Dec 31, 2017 | -107.3% | +656.2 |
| Q3 FY2017 | Sep 30, 2017 | -283.7% | +93.3 |
| Q2 FY2017 | Jun 30, 2017 | -231.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -548.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -763.6% | – |
| Q3 FY2016 | Sep 30, 2016 | -377.0% | – |
See a number that looks wrong?